

10th JUNE 2025

CARETEQ SECURES CONVERTIBLE NOTE FROM ANTANAS GUOGA

Careteq Limited (ASX: CTQ) ("Careteq" or "the Company"), a clinical healthtech company specialising in innovative medication management and clinical governance solutions, is pleased to announce it has entered in a binding convertible note agreement with Mr Antanas Guoga (Tony G) to raise \$500,000 for working capital purposes.

In addition, to support the working capital position of the company, all members of the Board including its Company Secretary have also entered into a binding loan agreement to raise \$125,000. The agreements bring in a total of \$625,000 in working capital to Careteq, ensuring the company is well placed funding wise for the medium term.

Tony Guoga is a world renowned investor, technology entrepreneur, philanthropist and former member of the European parliament for Lithuania (2014-2019). Tony has extensive technology sector experience across start-ups, business development, management, venture capital and is a strong advocate for innovation and entrepreneurship.

Key Highlights

- **Convertible Note from Tony Guoga (Schedule 1)**
 - Amount: \$500,000
 - Maturity Date: 4th June 2026
 - Interest Rate: 12% per annum (capitalised and added to the face value of the convertible note)
 - Convertible to fully paid shares at \$0.01 per share
- **Loan from Mark Simari (Chair)**
 - Loan Amount: \$26,500
 - Repayment Date: 4th June 2026
 - Interest Rate: 12% per annum (capitalised and added to the face value of the loan)
- **Loan from Stephen Munday (Non-Executive Director)**
 - Loan Amount: \$47,000
 - Repayment Date: 4th June 2026
 - Interest Rate: 12% per annum (capitalised and added to the face value of the loan)
- **Loan from Brett Cheong (Non-Executive Director)**
 - Loan Amount: \$26,500
 - Repayment Date: 4th June 2026
 - Interest Rate: 12% per annum (capitalised and added to the face value of the loan)
- **Loan from David Lilja (Company Secretary)**
 - Loan Amount: \$25,000
 - Repayment Date: 4th June 2026
 - Interest Rate: 12% per annum (capitalised and added to the face value of the loan)

SCHEDULE 1 – SUMMARY OF KEY TERMS OF CONVERTIBLE NOTE

Term	Detail
Issuer	Careteq Limited (ACN: 612 267 857)
Noteholder	Antanas Guoga
Amount	A\$500,000
Face Value	A\$1.00 per Convertible Note.
Maturity	The Convertible Notes will mature on 4 June 2026
Conversion Price	For all Conversion Events, the Convertible Notes will convert into Conversion Securities at a price of \$0.01 per share
Conversion Events	The Convertible Notes (including capitalised interest) will convert into fully paid ordinary shares in the capital of the Issuer (Conversion Securities) upon the earlier of: a) a trade sale of all, or substantially all, of the business or assets of the Issuer; b) a change of control (as defined in the Corporations Act) of the Issuer; and c) the Maturity Date.
Interest	Convertible Notes will accrue interest at the rate of 12% per annum which is to be capitalised and added to the face value of the Convertible Notes.

This ASX announcement has been authorised by the Board of Careteq Limited (ASX: CTQ)

For further information, please contact:

Careteq Limited (ASX: CTQ)

Mark Simari
Executive Chairman
P: +61 3 8866 5594
E: info@careteq.com.au

About Careteq Limited (ASX: CTQ)

Careteq Limited (ASX: CTQ) is an Australian healthtech company focused on innovative medication management solutions. The Company is dedicated to improving healthcare outcomes through its fully owned Embedded Health Solutions (EHS) and HMR Referrals platforms. EHS provides comprehensive aged care medication management solutions through Residential Medication Management Reviews (RMMRs), while HMR Referrals streamlines Home Medicines Reviews (HMRs).

To learn more, please visit: www.careteq.com.au/

Forward-looking statements

This announcement contains or may contain forward-looking statements that are based on Careteq's beliefs, assumptions, and expectations and on information currently available to Careteq. All statements that address operating performance, events or developments that Careteq or its directors expect or anticipate will occur in the future are forward-looking statements, including, without limitation, statements as to the expectations of Careteq or the market it operates in.

Careteq believes that these forward-looking statements are reasonable as and when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Careteq does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

No assurance or guarantee is, or should be taken to be, given in relation to, and no reliance should be placed on, the future business performance or results of Careteq or the likelihood that the current assumptions, estimates or outcomes will be achieved. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.

For more information



Follow us on [LinkedIn](#)

To learn more about Careteq please click here: <https://www.careteq.com.au/investors-centre/>

For personal use only